Skip to main content
OpenTrials
Completed

NCT Number: NCT05168995

Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control

The goal of asthma management is to achieve and maintain optimal asthma control. The NEWTON study assesses the evolution over time of patient reported outcomes (PROs) in asthmatic patients, not adequately controlled with ongoing treatments and initiating therapy with extrafine beclometasone dipropionate/formoterol fumarate (BDP/FF) via NEXThaler.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale dell'Angelo

Mestre, VE, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged ≥18 years;
  • Patients enrolled on the same day as the first prescription with BDP/FF NEXThaler® 100/6 micrograms, or having ongoing treatment with BDP/FF NEXThaler® 100/6 micrograms started within the previous 14 days (maximum), as per local standard clinical practice.
  • Not adequately controlled asthmatic patients (according to clinician's judgement) when BDP/FF NEXThaler® 100/6 micrograms was prescribed;
  • Patients not treated with extrafine formulations during the 6 months before starting the treatment with BDP/FF NEXThaler®;
  • Written informed consent to participate in the study and for the processing of personal data.

Exclusion criteria

  • Recent (i.e. within the last 6 months) history of life-threatening asthma exacerbations;
  • Diagnosis of chronic obstructive pulmonary disease (COPD);
  • Asthmatic patients on treatment with biologic agents (e.g. monoclonal antibodies) and/or extemporary or fixed triple combinations (e.g. long-acting β2 agonist (LABA)/long-acting muscarinic antagonist (LAMA)/inhaled corticosteroid (ICS) at any dose regimen;
  • Patients with uncontrolled/clinically significant diseases (according to clinician's judgement) or inability to understand and fill in study questionnaires;
  • Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study.

Treatment and study plan

BDP/FF NEXThaler® 100/6 micrograms

Drug

BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).

BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)

Primary outcomes

  1. Improvement of asthma control level using the 5-item Asthma Control Questionnaire

    Time frame: 6-month

    Proportion of patients improving the level of asthma control (based on ACQ-5 score).

    The ACQ-5 includes a measure of the top 5 asthma symptoms (woken at night by symptoms, day-time symptoms, limitation of daily activities, shortness of breath and wheeze) and the use of quick-relief bronchodilators.

    Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and use questions on a 7-point scale (0 = no impairment, 6 = maximum impairment). Patients' scores are then classified into three groups ('grouped scores') as having well-controlled asthma (ACQ-5 score ≤0.75); not well-controlled nor poorly controlled asthma (ACQ-5 score 0.75-1.5), or poorly controlled asthma (ACQ-5 score ≥1.5)

Secondary outcomes

  1. Improvement of asthma control level using the 5-item Asthma Control Questionnaire

    Time frame: 3 months

    Proportion of patients improving the level of asthma control (based on ACQ-5 score)

  2. Achievement of minimal clinically important improvement in ACQ-5 score

    Time frame: 6 months

    Proportion of patients achieving minimal clinically important improvement in ACQ-5 scores, as defined by ACQ-5 score decrease of at least 0.5 points

  3. Assessment of quality of life using EuroQol 5-dimension 5-level version (EQ-5D-5L)

    Time frame: 3 and 6 months

    Change in EQ-5D-5L score. It consists of 2 pages, a descriptive system and a visual Analogue scale. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each dimension having 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.The VAS records the respondent's self-rated health on a 10 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'.

  4. Assessment of adherence to treatment using 12-item Test of Adherence to Inhalers (TAI-12)

    Time frame: 3 and 6 months

    Change in TAI-12 score. TAI comprises a patient domain (including 10 items) and a healthcare professional domain (including 2 items). Each item ranges from 1 (lowest adherence) to 5 (highest adherence) points. The patient domain score ranges from 10 to 50. Adherence is rated as good (score =50), intermediate (score = 46-49), or poor (score ≤45). The questions for healthcare professionals are scored with 1 or 2 points (poor or good knowledge of the regimen and/or inhalation technique).

  5. Structured questions on patient satisfaction about the inhaler

    Time frame: 3 and 6 months

    Three questions related to the satisfaction for the device will be administered to patients who will express the grade of agreement.

    The 3 questions are scored on a 0-4 Likert scale, which range from 0 (completely unsatisfied) to 4 (completely satisfied), for a total maximum score of 12. Higher scores indicate a higher satisfaction with the inhaler.

  6. Asthma exacerbations

    Time frame: 6 months

    Occurrence of moderate-to-severe exacerbations

  7. Adverse events

    Time frame: 6 months

    Number of AEs

  8. Adverse drug reactions to BDP/FF NEXThaler

    Time frame: 6 months

    Number of ADRs

Sponsors and collaborators

Lead sponsor

Chiesi Italia

Industry

Registry information

Official study title

Effects of Beclometasone Dipropionate/Formoterol Fumarate Fixed Combination Administered With the NEXT(Haler) in a Real-world Study on the Probability of Improving the Asthma Control Status After 6 Months of Treatment. The NEWTON Study

Acronym: NEWTON

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 23, 2021
Registry last updated
Feb 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.